Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. Roy T, An JB, Doucette K, Chappell AM, et al. Leuk Lymphoma 2022 Jan 25:1-3. doi: 10.1080/10428194.2021.2010065.

Read + Share

Amedeo Smart

Independent Medical Education

Roy T, An JB, Doucette K, Chappell AM, et al. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. Leuk Lymphoma 2022 Jan 25:1-3. doi: 10.1080/10428194.2021.2010065.
PMID: 35076333